Advanced-Stage Cancer
Home » Advanced-Stage Cancer

How precision oncology is improving care for patients with advanced stage cancer

Recent advancements in testing and treatment are providing greater hope for patients. Precision oncology, or personalizing cancer treatment to each individual, is helping doctors optimize care for patients across all stages of the disease.

For patients with advanced stage cancer, precision oncology has made a radical difference over the past decade in improving outcomes across cancer types, including lung, breast, colorectal, and prostate. Precision medicine, also known as targeted therapy or personalized medicine, uses drugs to target the specific genes and proteins, also known as biomarkers, that are causing a person’s cancer cells to grow. This personalized, biomarker-informed approach can improve progression-free survival with fewer side effects than traditional one-size-fits-all chemotherapy or immunotherapy.1

In order to identify these targetable biomarkers and determine if there is an appropriate therapy or clinical trial, it is necessary that doctors perform complete genomic testing (also known as comprehensive genomic profiling, biomarker testing, or molecular profiling). Performing genomic testing using a blood test does not require tissue testing, enabling potentially more patients to be matched with targeted therapies.

Click the button below to find out more about testing for advance stage cancer.

Check out this patient education video featuring Dr. Akhil Chopra, a senior medical oncologist from OncoCare Cancer Centre (Singapore), where he shares how the Guardant360® liquid biopsy test helped to guide treatment decisions for patients with advanced-stage lung cancer in his clinical practice.

Hear from Prof. Cho Byoung Chul, Chief of the Lung Cancer Center in Yonsei Cancer Center in Seoul, South Korea as he shares his experience of using the Guardant360® test in his clinic.

References

1. Aggarwal C, Thompson JC, Chien A, et al. Dynamic monitoring of circulating tumor DNA next-generation gene sequencing as a predictive biomarker of response and progression-free survival after pembrolizumab monotherapy in patients with advanced NSCLC.J Clin Oncol; 2019: 37:15 suppl, 3040-3040. DOI:10.1200/JCO.2019.37.15.

Email Us

Message us